ADS-ADEA 2016* , ,
Presentations this author is a contributor to:
Quantifying and Predicting Mean A1C Reductions for Exenatide QW and BID: Importance of Baseline A1C and Other Patient Characteristics (#56)
3:30 PM
Jonathan Shaw
ADS Clinical Orals - Type 2 Therapies
Effects of linagliptin on glycemic control and albuminuria in type 2 diabetes - the MARLINA–T2D™ trial (#62)
5:00 PM
Per-Henrik Groop
ADS Clinical Orals - Type 2 Therapies